TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) IN COMBINATION ARE NOT ANTAGONISTIC BUT PRODUCE EXTENDED GRAFT SURVIVAL IN CARDIAC TRANSPLANTATION IN THE RAT1,2

Abstract
Combined use of tacrolimus (FK506) with sirolimus (rapamycin [RAPA]) was examined in a model of vascularized heart allograft in the rat. For prevention of acute rejection, three different combinations of low doses of FK506 and RAPA from day 1 up to day 14 after transplantation produced significantly longer cardiac allograft survival than each agent alone( P P P .